Biotech Acquisition Company Unit
BIOTU
BIOTU was delisted on the 2nd of February, 2023.
15 hedge funds and large institutions have $5.18M invested in Biotech Acquisition Company Unit in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 21 closing their positions.
56% less funds holding
Funds holding: 34 → 15 (-19)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
89% less capital invested
Capital invested by funds: $45.2M → $5.18M (-$40M)
90% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIA
SkyView Investment Advisors
Shrewsbury,
New Jersey
|
+$32.2K |
| 2 |
BCM
BCK Capital Management
Stamford,
Connecticut
|
+$4.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$11.5M |
| 2 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
-$11.1M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$4.45M |
| 4 |
GCL
Glazer Capital LLC
New York
|
-$3.11M |
| 5 |
CCM
Context Capital Management
Lajolla,
California
|
-$1.95M |
BIOTU Hedge Fund Activity: Q4 2021 in Review
15 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Unit (BIOTU) for Q4 2021, worth a combined $5.18M — down 89% from $45.2M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of BIOTU and 2 opened new positions — a net loss of 19 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was SkyView Investment Advisors, opening a new position worth an estimated $32.2K. The largest seller was Aristeia Capital, exiting entirely with an estimated $11.5M sold.
- 15 institutional investors held Biotech Acquisition Company Unit (BIOTU) as of Q4 2021, down from 34 in Q3 2021.
- Funds reported $5.18M of Biotech Acquisition Company Unit stock for Q4 2021, down 89% quarter-over-quarter.
- 2 funds opened new Biotech Acquisition Company Unit positions in Q4 2021 and 21 closed out, a net change of -19 holders.
- The largest Biotech Acquisition Company Unit buyer in Q4 2021 was SkyView Investment Advisors, an estimated $32.2K added.
- The largest Biotech Acquisition Company Unit seller in Q4 2021 was Aristeia Capital, an estimated $11.5M sold.
Based on aggregated 13F filings for Q4 2021.